Janssen Pharmaceuticals, Inc.

Biocerox Products B.v.

Broteio Pharma B.v.

Jjp Biologics Sp. Z O.o.

Polpharma Biologics S.a.

Louis Boon

Petrus Johannes Simons

Jinquan Luo

Randall J Brezski

Cornelis Erik Hack

Cafer Yildiz

Monica Goldberg

Marcel Theodorus Den Hartog

Lenneke De Winter

Tomasz Sitar

Anti-Human Hvem (TNFRSF14) Antibodies And Uses Thereof

The invention discloses an antibody that can bind an extra-cellular part of human CD89 (human FcαRI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells and that induces less cell death in said human CD89 expressing cells when compared to the antibody MIP8a. The invention also disclosed the use of such antibodies in combating certain diseases.

Anti-human CD89 antibodies and uses thereof

The invention provide a method for reducing the amount of acidic species and/or increasing the amount of basic species in a composition comprising a recombinant protein or for increasing the specific production rate of mammalian cells expressing a recombinant protein to simplify subsequent clarification and purification of the recombinant protein, said method comprising culturing mammalian cells expressing said recombinant protein in a cell culture medium comprising citrulline.

Methods of cell culture

The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.

Binding molecules that bind human complement factor C2 and uses thereof

The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Humanized anti-CD134 (OX40) antibodies and uses thereof

The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.

The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Growing community of inventors

Badhoevedorp, Netherlands

Louis Boon